JP6352812B6 - 抗ｃｘｃｒ３抗体 - Google Patents

抗ｃｘｃｒ３抗体 Download PDF

Info

Publication number
JP6352812B6
JP6352812B6 JP2014553482A JP2014553482A JP6352812B6 JP 6352812 B6 JP6352812 B6 JP 6352812B6 JP 2014553482 A JP2014553482 A JP 2014553482A JP 2014553482 A JP2014553482 A JP 2014553482A JP 6352812 B6 JP6352812 B6 JP 6352812B6
Authority
JP
Japan
Prior art keywords
antibody
cxcr3
amino acid
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014553482A
Other languages
English (en)
Japanese (ja)
Other versions
JP6352812B2 (ja
JP2015506945A5 (cg-RX-API-DMAC7.html
JP2015506945A (ja
Inventor
ミシェル・ユード
ジェニファー・テッドストーン
トレイシー・ロディー
カレン・ビー・カーター
ティモシー・ディー・コナーズ
ジェイソン・ロバート・ピンクニー
エリザベス・マスタージョン
ルイイン・チュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2015506945A publication Critical patent/JP2015506945A/ja
Publication of JP2015506945A5 publication Critical patent/JP2015506945A5/ja
Publication of JP6352812B2 publication Critical patent/JP6352812B2/ja
Application granted granted Critical
Publication of JP6352812B6 publication Critical patent/JP6352812B6/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014553482A 2012-01-20 2013-01-18 抗ｃｘｃｒ３抗体 Expired - Fee Related JP6352812B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20
US61/588,936 2012-01-20
PCT/US2013/022280 WO2013109974A2 (en) 2012-01-20 2013-01-18 Anti-cxcr3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018089004A Division JP6646100B2 (ja) 2012-01-20 2018-05-07 抗ｃｘｃｒ３抗体

Publications (4)

Publication Number Publication Date
JP2015506945A JP2015506945A (ja) 2015-03-05
JP2015506945A5 JP2015506945A5 (cg-RX-API-DMAC7.html) 2016-03-03
JP6352812B2 JP6352812B2 (ja) 2018-07-04
JP6352812B6 true JP6352812B6 (ja) 2018-08-08

Family

ID=47633576

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014553482A Expired - Fee Related JP6352812B6 (ja) 2012-01-20 2013-01-18 抗ｃｘｃｒ３抗体
JP2018089004A Expired - Fee Related JP6646100B2 (ja) 2012-01-20 2018-05-07 抗ｃｘｃｒ３抗体
JP2020001152A Pending JP2020072715A (ja) 2012-01-20 2020-01-08 抗ｃｘｃｒ３抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018089004A Expired - Fee Related JP6646100B2 (ja) 2012-01-20 2018-05-07 抗ｃｘｃｒ３抗体
JP2020001152A Pending JP2020072715A (ja) 2012-01-20 2020-01-08 抗ｃｘｃｒ３抗体

Country Status (26)

Country Link
US (4) US8865870B2 (cg-RX-API-DMAC7.html)
EP (1) EP2804878B1 (cg-RX-API-DMAC7.html)
JP (3) JP6352812B6 (cg-RX-API-DMAC7.html)
KR (2) KR20200014441A (cg-RX-API-DMAC7.html)
CN (1) CN104507967B (cg-RX-API-DMAC7.html)
AR (1) AR090056A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013209492B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014017814A8 (cg-RX-API-DMAC7.html)
CA (1) CA2862222A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121335T1 (cg-RX-API-DMAC7.html)
DK (1) DK2804878T3 (cg-RX-API-DMAC7.html)
ES (1) ES2698606T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181874T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041900T2 (cg-RX-API-DMAC7.html)
IL (2) IL233694A0 (cg-RX-API-DMAC7.html)
LT (1) LT2804878T (cg-RX-API-DMAC7.html)
MX (1) MX359854B (cg-RX-API-DMAC7.html)
PL (1) PL2804878T3 (cg-RX-API-DMAC7.html)
PT (1) PT2804878T (cg-RX-API-DMAC7.html)
RS (1) RS58141B1 (cg-RX-API-DMAC7.html)
RU (1) RU2663141C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201406762QA (cg-RX-API-DMAC7.html)
SI (1) SI2804878T1 (cg-RX-API-DMAC7.html)
TW (1) TWI596112B (cg-RX-API-DMAC7.html)
UY (1) UY34582A (cg-RX-API-DMAC7.html)
WO (1) WO2013109974A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
SG11201701382PA (en) * 2014-08-22 2017-03-30 Sorrento Therapeutics Inc Antigen binding proteins that bind cxcr3
CN116003596A (zh) * 2015-10-29 2023-04-25 艾利妥 抗siglec-9抗体及其使用方法
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
KR20190095942A (ko) * 2016-12-22 2019-08-16 사노피 백반증의 치료를 위한 항-인간 cxcr3 항체
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
WO2018119299A1 (en) 2016-12-22 2018-06-28 Sanofi Humanized cxcr3 antibodies with depleting activity and methods of use thereof
CA3091311A1 (en) 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
KR102074798B1 (ko) * 2018-06-15 2020-02-07 코아스템(주) 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
BR112021009325A2 (pt) 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
PT3872091T (pt) 2020-02-26 2023-09-19 Vir Biotechnology Inc Anticorpos contra sars-cov-2
WO2021222746A2 (en) * 2020-04-30 2021-11-04 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CA3210655A1 (en) * 2021-03-02 2022-09-09 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN120112292A (zh) 2022-09-09 2025-06-06 爱杜西亚药品有限公司 包含抗-cd3抗体及cxcr3拮抗剂的药物组合

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3546806C2 (cg-RX-API-DMAC7.html) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
JP4502408B2 (ja) * 1996-09-10 2010-07-14 テオドーア−コッヒャー インスティトゥーテ Ｃｘｃｒ３ケモカイン受容体、抗体、核酸および使用方法
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001072334A2 (en) * 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
CA2536644A1 (en) * 2003-06-30 2005-02-03 Bio-Technology General (Israel) Ltd. Antibodies and uses thereof
US7405275B2 (en) 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
EA014112B1 (ru) * 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
RU2007108538A (ru) 2004-08-11 2008-09-20 Трабьон Фармасьютикалз, Инк. (Us) Слитые со связывающим доменом белки
BRPI0710011A2 (pt) 2006-04-14 2011-08-02 Trubion Pharmaceuticals Inc proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas
KR20100014869A (ko) * 2007-02-01 2010-02-11 테바 바이오파머수티컬스 유에스에이, 아이엔씨. Ｃｘｃｒ3에 대한 인간화 항체
PT2195023T (pt) 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
US20100130476A1 (en) 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) * 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
NO2539366T3 (cg-RX-API-DMAC7.html) * 2010-02-26 2018-04-07

Also Published As

Publication number Publication date
US20180086838A1 (en) 2018-03-29
CN104507967B (zh) 2018-10-12
SI2804878T1 (sl) 2018-12-31
KR20140116525A (ko) 2014-10-02
JP6646100B2 (ja) 2020-02-14
WO2013109974A2 (en) 2013-07-25
JP6352812B2 (ja) 2018-07-04
RU2663141C2 (ru) 2018-08-01
KR20200014441A (ko) 2020-02-10
JP2018166506A (ja) 2018-11-01
JP2020072715A (ja) 2020-05-14
KR102073034B1 (ko) 2020-02-05
US20140377806A1 (en) 2014-12-25
EP2804878B1 (en) 2018-08-22
US20190119391A1 (en) 2019-04-25
JP2015506945A (ja) 2015-03-05
DK2804878T3 (en) 2018-12-17
IL271697A (en) 2020-02-27
ES2698606T3 (es) 2019-02-05
HRP20181874T1 (hr) 2019-01-11
AU2013209492B2 (en) 2018-02-08
RU2014134043A (ru) 2016-03-20
BR112014017814A2 (cg-RX-API-DMAC7.html) 2017-06-20
CY1121335T1 (el) 2020-05-29
HK1208684A1 (en) 2016-03-11
EP2804878A2 (en) 2014-11-26
HUE041900T2 (hu) 2019-06-28
IL233694A0 (en) 2014-09-30
LT2804878T (lt) 2018-12-10
PT2804878T (pt) 2018-11-29
WO2013109974A3 (en) 2013-11-07
BR112014017814A8 (pt) 2017-07-11
MX2014008728A (es) 2015-07-06
AR090056A1 (es) 2014-10-15
TWI596112B (zh) 2017-08-21
RS58141B1 (sr) 2019-02-28
MX359854B (es) 2018-10-12
SG10201700735PA (en) 2017-02-27
AU2013209492A1 (en) 2014-08-14
US8865870B2 (en) 2014-10-21
CN104507967A (zh) 2015-04-08
TW201335188A (zh) 2013-09-01
SG11201406762QA (en) 2014-11-27
US20130251733A1 (en) 2013-09-26
CA2862222A1 (en) 2013-07-25
PL2804878T3 (pl) 2019-03-29
UY34582A (es) 2013-09-02
US9765144B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
JP6352812B6 (ja) 抗ｃｘｃｒ３抗体
KR102163001B1 (ko) 알파-시누클레인을 인식하는 항체
JP2021184731A (ja) Ｃｄ１２７に対する抗体
TW201900679A (zh) 細胞毒性t淋巴球相關蛋白4 (ctla-4) 之新穎單株抗體
JP2010518873A (ja) アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
US20170342148A1 (en) Anti il-34 antibodies
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
US20220411527A1 (en) Compositions and methods for transferrin receptor 1 targeting
WO2018119299A1 (en) Humanized cxcr3 antibodies with depleting activity and methods of use thereof
US20230416375A1 (en) Antibody variants against wnt receptor ryk
HK1208684B (zh) 抗cxcr3抗體
JP2025529623A (ja) ヒト化抗ヒトニューロテンシン受容体１抗体及びそれらの使用
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180607

R150 Certificate of patent or registration of utility model

Ref document number: 6352812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees